Histology

PathAI and Summit Clinical Research Launch a Comprehensive NASH Clinical Trial Services Solution to Optimize Trial Success

Wednesday, September 22, 2021 - 1:30pm

Together, PathAI and Summit aim to alleviate many key challenges facing NASH drug development progress, including high site activation costs, barriers to subject enrollment, slow diagnostic turnaround time, and significant variability and inaccuracy in NASH histology scoring.

Key Points: 
  • Together, PathAI and Summit aim to alleviate many key challenges facing NASH drug development progress, including high site activation costs, barriers to subject enrollment, slow diagnostic turnaround time, and significant variability and inaccuracy in NASH histology scoring.
  • Summit brings its track record of supporting many of the most active middle- and late-stage NASH drug development programs to the partnership.
  • PathAI and Summit have already contracted with a sponsor to provide pathology services for a phase 2 clinical trial, with several additional trials under negotiation.
  • PathAI is a leading provider of AI-powered research tools and services for pathology.

Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Wednesday, September 22, 2021 - 1:00pm

NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.

Key Points: 
  • NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.
  • Additional details can be found below:
    A replay of the presentation will be available by visiting the " Events & Presentations " section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A

Wednesday, September 22, 2021 - 6:00am

The GABAB receptor has previously been shown to be instrumental in controlling the overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat model of CMT1A.

Key Points: 
  • The GABAB receptor has previously been shown to be instrumental in controlling the overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat model of CMT1A.
  • Strategic alliances with pharmaceutical partners like Addex Therapeutics support drug development efforts to deliver therapies to CMT patients.
  • We are excited to establish this partnership with Addex Therapeutics as they work to advance their PAMs to treat CMT1A, said CMTAs CEO Amy Gray.
  • Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.

Olympus Strengthens Surgical Portfolio with the Launch of POWERSEAL Advanced Bipolar Surgical Energy Devices

Tuesday, September 21, 2021 - 4:00am

[i]

Key Points: 
  • [i]
    The POWERSEAL 5mm Curved Jaw Tissue Sealer and Divider, Double-Action
    With the release of the POWERSEAL devices, Olympus is introducing a line of versatile advanced bipolar surgical energy devices that augment an extensive and differentiated surgical energy portfolio, which features the unique THUNDERBEAT(TM) hybrid energy devices and SONICBEAT(TM) ultrasonic dissectors.
  • The POWERSEAL devices position Olympus competitively within the growing global market for advanced bipolar surgical energy devices, currently estimated at over $1.2B USD.
  • "[v]
    The Olympus Energy platform, made up of the ESG-400(TM) and USG-400(TM) electrosurgical generators, offers hospitals a complete energy solution for any operating room and powers the full range of Olympus Energy systems: monopolar, bipolar (HiQ (TM), HICURA (TM), PK (TM) and Everest (TM) devices), ultrasonic (SONICBEAT devices), hybrid energy (THUNDERBEAT devices) and advanced bipolar (POWERSEAL devices).
  • Advanced bipolar energy devices are distinguished from traditional bipolar energy devices through more efficient energy delivery, intuitive tissue monitoring, and uniform pressure applied to the tissue by the device jaws.

Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer

Monday, September 20, 2021 - 4:30pm

The data is being presented today in an oral presentation at the 2021 ESMO Congress.

Key Points: 
  • The data is being presented today in an oral presentation at the 2021 ESMO Congress.
  • We believe this approach could unlock significant opportunities for SY-5609 and achieve the transformative potential of CDK7 inhibition for people with difficult-to-treat cancers.
  • Patients had been heavily pre-treated with as many as eight prior therapies and a median of four prior therapies.
  • Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for the treatment of pancreatic cancer in the fourth quarter of 2021.

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

Sunday, September 19, 2021 - 4:30pm

The 12-month probability of survival was 66% for the Libtayo combination and 56% for chemotherapy.

Key Points: 
  • The 12-month probability of survival was 66% for the Libtayo combination and 56% for chemotherapy.
  • The 12-month probability of PFS was 38% for the Libtayo combination and 16% for chemotherapy.
  • The Libtayo combination also improved pain symptoms, compared to chemotherapy (-4.98 difference in baseline changes between treatment groups; 95% CI: -8.36 to -1.60; nominal p=0.004).
  • Treatment discontinuation due to AEs occurred in 5% of patients receiving the Libtayo combination and 3% receiving chemotherapy.

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021

Tuesday, September 14, 2021 - 4:36am

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Key Points: 
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • This release discusses investigational compounds and investigational uses for FDA-approved products.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021

Monday, September 13, 2021 - 12:00pm

The oral presentation will include safety, tolerability, and initial clinical activity data for SY-5609 in patients with breast, colorectal, lung, ovarian and pancreatic cancers, as well as in patients with solid tumors of any histology harboring Rb pathway alterations.

Key Points: 
  • The oral presentation will include safety, tolerability, and initial clinical activity data for SY-5609 in patients with breast, colorectal, lung, ovarian and pancreatic cancers, as well as in patients with solid tumors of any histology harboring Rb pathway alterations.
  • The abstract for the oral presentation on the Phase 1 dose-escalation data will remain embargoed until September 17 at 00:05 CEST (September 16 at 6:05 p.m.
  • ET to discuss the new clinical and preclinical data for SY-5609, which will be presented at the ESMO Congress 2021.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .

Neoadjuvant Atezolizumab in Combination with Cisplatin/Pemetrexed and as Maintenance for Resectable Pleural Mesothelioma Meets Safety Criteria

Sunday, September 12, 2021 - 4:30pm

Safety was defined as no Grade 4-5 immune-related adverse event; feasible if 18/24 (75%) received at least one dose of maintenance therapy. Patients were divided into two cohorts --the pleurectomy/decortication cohort or the extrapleural penomonectomy cohort.

Key Points: 
  • Safety was defined as no Grade 4-5 immune-related adverse event; feasible if 18/24 (75%) received at least one dose of maintenance therapy.
  • Patients received four cycles of neoadjuvant cisplatin and pemetrexed plus atezolizumab (CPA), resection, then radiation (EPP cases only), followed by one year of maintenance atezolizumab.
  • Twenty-eight eligible patients were enrolled (Nov 2017 - May 2020); 25 received at least two cycles of neoadjuvant CPA, 18 underwent surgery, and 15 received maintenance atezolizumab.
  • "Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria," said Dr. Tsao.

Olympus Strengthens Surgical Portfolio with the Launch of POWERSEAL Advanced Bipolar Surgical Energy Devices

Thursday, September 9, 2021 - 7:00pm

CENTER VALLEY, Pa., Sept. 9, 2021 /PRNewswire/ -- Olympus today announced the launch of the first devices in the new POWERSEAL family of advanced bipolar surgical energy products.

Key Points: 
  • CENTER VALLEY, Pa., Sept. 9, 2021 /PRNewswire/ -- Olympus today announced the launch of the first devices in the new POWERSEAL family of advanced bipolar surgical energy products.
  • With the release of the POWERSEAL devices, Olympus is introducing a line of versatile advanced bipolar surgical energy devices that augment an extensive and differentiated surgical energy portfolio, which features the unique THUNDERBEAT hybrid energy devices and SONICBEAT ultrasonic dissectors.
  • The POWERSEAL devices position Olympus competitively within the growing global market for advanced bipolar surgical energy devices, currently estimated at over $1.2B USD.
  • The Olympus Energy platform, made up of the ESG-400 and USG-400 electrosurgical generators, offers hospitals a complete energy solution for any operating room and powers the full range of Olympus Energy systems: monopolar, bipolar (HiQ , HICURA , PK and Everest devices), ultrasonic (SONICBEAT devices), hybrid energy (THUNDERBEAT devices) and advanced bipolar (POWERSEAL devices).